Brief: Cantargia Successfully Concludes Toxicity Study With CAN10 Antibody

Cantargia AB

13/01/2023 11:34

Jan 13 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA SUCCESSFULLY CONCLUDES TOXICITY STUDY WITH CAN10
ANTIBODY AHEAD OF PHASE I CLINICAL TRIAL APPLICATION
    * DATA FROM STUDY SHOW THAT CAN10 WAS WELL TOLERATED WHEN
ADMINISTERED OVER SIX WEEKS
    * CANTARGIA PLANS TO INITIATE PHASE I CLINICAL TRIAL FOR
CAN10
DURING FIRST HALF OF 2023

Source text for Eikon:  ID:nWkr60ThcB 
Further company coverage:  CANTA.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))